CBO Overestimates Costs Of Enforcing DXM Sales Age-Restriction – CHPA

The Consumer Healthcare Products Association contends the Congressional Budget Office made a flawed comparison to FDA's Tobacco Retail Compliance Check program when it estimated federal costs from age-restricting sales of dextromethorphan-containing OTC drugs.

To determine its estimate of $232m over five years for the costs of enforcing a ban Congress is considering on sales of DXM-containing OTCs to minors, CBO considered FDA’s reliance on “similar activities” it conducts under the Center for Tobacco Products’ program that monitors retailers' compliance with requirements of the 2009